ArticleJournal of translational medicine2026
Multimodal transcriptomics reveal myCAF-derived collagen signaling associated with impaired NK-cell cytotoxicity and immune exclusion in pancreatic cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The tumor microenvironment in pancreatic cancer: from composition to therapeutic targeting.Biochemical Society transactions · 2026Review
- Innate immunity-stroma crosstalk in pancreatic cancer: overcoming spatial and metabolic barriers to immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite years of research, pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. A highly fibrotic, immunosuppressive microenvironment poses a significant barrier to effective immunotherapy. As key innate immune effectors of antitumor immunity, the functional status of natural killer (NK) cells within this environment remains poorly understood. This study aims to explore the role of stromal-immune interactions, particularly myofibroblastic cancer-associated fibroblasts (myCAFs) and NK cells, in shaping immune dysfunction in PDAC.
methodsWe integrated spatial, single-cell and bulk transcriptomic analyses to characterize NK-cell heterogeneity and its cellular and molecular regulation in PDAC. CellChat-based communication analysis, spatial co-localization, and multiplex immunofluorescence were utilized to identify regulatory interactions and validate spatial associations.
resultsA tumor-associated NK (TaNK) subset with impaired cytotoxicity was identified. myCAFs strongly interacted with TaNK cells through collagen signaling. Within ligand-receptor pairs, COL1A2-CD44 and COL1A1-LAIR1 served as dominant mediators linking stromal remodeling to impaired NK cell function. Spatial and histological validation confirmed their co-localization, while tumors co-enriched with myCAFs and TaNKs exhibited immune exclusion and poor response to immunotherapy.
conclusionsOur study demonstrates that collagen signaling from myCAFs impairs NK-cell cytotoxicity and promotes immune exclusion in PDAC. These findings advance the understanding of stromal-immune mechanisms underlying immunotherapy resistance and highlight that targeting the myCAF-NK axis may help improve the response to immunotherapy in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.